Logo
x

Search category

Subscribe Now

Sierra Oncology

Barbara Klencke, CMO at Sierra Oncology (now GSK) Shares Insights on the Significant benefits obtained from the Pivotal Myelofibrosis Study

Barbara Klencke, CMO at Sierra Oncology (now GSK) Shares Insights on the Significant benefits obtained from the Pivotal Myelofibro...

  • July 18, 2022
Sierra Oncology Reports NDA Submission of Momelotinib to the US FDA for the Treatment of Myelofibrosis

Sierra Oncology Reports NDA Submission of Momelotinib to the US FDA for the Treatment of Myelofibrosis

  • June 17, 2022
PharmaShots Weekly Snapshots (June 13– 17, 2022)

PharmaShots Weekly Snapshots (June 13– 17, 2022)

  • June 17, 2022
Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

  • January 27, 2022
Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

  • January 27, 2022
PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra's Agreement with AstraZeneca for AZD5153

PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra's Agreement with AstraZeneca for AZD5153

  • October 11, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.